R348 Ophthalmic Solution, 0.2%

DRUG3 trials

Sponsors

Rigel Pharmaceuticals

Conditions

Chronic Graft-versus-host DiseaseKeratoconjunctivitis Sicca

Phase 1

A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease

CompletedNCT01733992

Rigel PharmaceuticalsKeratoconjunctivitis Sicca

Start: 2012-11-30End: 2013-02-28Updated: 2014-08-04

Phase 2

To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca

CompletedNCT01900249

Rigel PharmaceuticalsKeratoconjunctivitis Sicca

Start: 2013-07-31End: 2014-07-31Updated: 2016-10-03

Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)

CompletedNCT02040623

Rigel PharmaceuticalsChronic Graft-versus-host Disease

Start: 2014-03-31End: 2016-07-31Updated: 2016-10-10